For the first time since 2011, a US Food and Drug Administration advisory committee will consider whether an accelerated approval drug should continue to be marketed given the failure of a postmarketing trial to verify clinical benefit.
On 29 October, the agency’s Bone, Reproductive and Urologic Drugs Advisory Committee will re-evaluate the regulatory status of AMAG...